Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2007 / Cilt: 17 - Sayı: 1

The development of Hodgkin lymphoma in male patient with systemic lupus erythematosus and secondary antiphospholipid syndrome

Sistemik lupus eritematozus ve sekonder antifosfolipid sendromlu bir erkek hastada Hodgkin lenfoma gelişimi: Bir olgu sunumu ve literatürün gözden geçirilmesi

Pages
37–41
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although SLE is a disease which may cause lymphadenopathy and B symptoms, when these symptoms develop in a SLE patient in remission, lymph node biopsy should be taken to rule out the possibility of lymphoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are some data that the frequency of malignancy increases in some autoimmune diseases.
📊
Key Findings & Data:The development of Hodgkin’s lymphoma in patients with systemic lupus erythematosus (SLE) has been reported rarely.
💡
Conclusion & Impact:Although SLE is a disease which may cause lymphadenopathy and B symptoms, when these symptoms develop in a SLE patient in remission, lymph node biopsy should be taken to rule out the possibility of lymphoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hodgkin hastalığı · Lupus eritematozus · sistemik

Abstract

There are some data that the frequency of malignancy increases in some autoimmune diseases. The development of Hodgkin’s lymphoma in patients with systemic lupus erythematosus (SLE) has been reported rarely. Here, we presented a young male SLE patient who had recurrent thrombophlebitis and deep venous thrombosis, secondary antiphospholipids syndrome, and who has been using cyclophosphamide and corticosteroids for 1.5 years for lupus nephritis. After a follow-up of 1.5 years, he developed fever, night sweats and lymphadenopathy. Lymph node biopsy was compatible with mixed-cellular type Hodgkin’s lymphoma, and he was in complete hematologic remission after ABVD chemotherapy. Although SLE is a disease which may cause lymphadenopathy and B symptoms, when these symptoms develop in a SLE patient in remission, lymph node biopsy should be taken to rule out the possibility of lymphoma.

Özet

Otoimmün bazı hastalıklarda, malignite sıklığının arttığına dair veriler bulunmaktadır. Sistemik lupus eritematozuslu (SLE) hastalarda, Hodgkin lenfoma gelişimi oldukça nadir olarak bildirilmiştir. Biz burada lupus nefriti nedeniyle yaklaşık 1.5 yıldır siklofosfamid ve kortikosteroid kullanan, reküren trombofilebitleri ve geçirilmiş derin ven trombozu olan, sekonder antifosfolipid sendromlu, genç erkek bir SLE olgusunu sunduk. Olguda, 1.5 yıl izlem sonunda ateş, gece terlemesi, ve lenfadenopati gelişti. Yapılan lenf bezi biyopsisi mikst sellüler tip Hodgkin lenfoma ile uyumlu saptanan hasta, 8 kür ABVD protokolü sonrasında tam remisyona girdi. SLE lenfadenopati ve B semptomlarına yol açabilen bir hastalık olmasına rağmen, remisyonda seyreden SLE’li bir hastada bu semptomlar gelişirse lenfoma gelişimi olasılığı düşünülerek vakit kaybetmeden lenf bezi biyopsisi yaptırılmalıdır

🔖

Cite This Article

PAMUK, G., PAMUK, Ö. N., TEKGÜNDÜZ, E., TURGUT, B., DEMİR, M., ÇAKIR, N. (2007). The development of Hodgkin lymphoma in male patient with systemic lupus erythematosus and secondary antiphospholipid syndrome. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 17 - Sayı: 1, 37–41. https://ajindex.com/articles/323014

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 10: 394-400, 2001
  2. Bjömadal L, Löfström B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31: 66-71, 2002
  3. Papadaki HA, Xylouri I, Katrinakis G, et al. Non-Hodgkin’s lymphoma in patients with systemic lupus erythematosus. Leukemia&Lymphoma 44: 275-279, 2003
  4. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165: 2337-2344, 2005
  5. Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 39:1147-1152, 2000
  6. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy-is there an association? Scand J Rheumatol 30: 185-188, 2001
  7. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437-439, 1992
  8. Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40: 761-768, 1997
  9. Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Invest Med 46: 217-222, 1998
  10. Abu-Shakra M, Cladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 39: 1050-1054, 1996
  11. Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 22: 1478-1482, 1995
  12. Lewis RB, Castor CW, Knisley RE, Bole GG. Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 19: 1256-1260, 1976
  13. Nived O, Bengtsson A, Jönsen A, et al. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10: 500- 504, 2001
  14. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52: 1481-90, 2005
  15. Goodwin JS. Remission in systemic lupus erythematosus after combination chemotherapy for Hodgkin's disease. JAMA 244: 1962, 1980
  16. Bhalla R, Ajmani HS, Kim WW, et al. Systemic lupus erythematosus and Hodgkin’s lymphoma. J Rheumatol 20: 1316-1320, 1993
  17. Efremidis A, Eiser AR, Grishman E, Rosenberg V